Cytokinetics Inc - Company Profile
Powered by
All the data and insights you need on Cytokinetics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Cytokinetics Inc Strategy Report
- Understand Cytokinetics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on Cytokinetics Inc’s latest deals, number of deals and deal values, alongside insights into its key mergers and acquisitions.
Number of Deals
Deal Value ($M)
Latest Deals
Announced Date | Headline | Deal Type | Acquirers/Investors/Surviving Entity | Issuer/Partner/Target |
---|---|---|---|---|
01 Jul 2022 | Cytokinetics Prices Private Placement of 3.50% Convertible Senior Notes Due 2027 for USD450 Million | Debt Offering | - |
Cytokinetics Inc |
07 Jan 2022 | Royalty Pharma Acquires Royalty Rights for Aficamten from Cytokinetics | Asset Transaction |
Royalty Pharma Plc
|
Cytokinetics Inc |
07 Jan 2022 | Royalty Pharma Acquires Royalty Rights for Omecamtiv Mecarbil from Cytokinetics | Asset Transaction |
Royalty Pharma Plc
|
Cytokinetics Inc |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
Contact the team or request a demo to find out how our data can drive your business forward
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer